Alkem laboratories has announced a key senior management appointment, strengthening its leadership team with an experienced sales professional. The pharmaceutical company disclosed the appointment under regulatory compliance requirements to stock exchanges.

Senior Management Appointment Details

The company has appointed Mr. Samsheer Kumar Deo to a senior management position effective from 27th March, 2026. The appointment was formally communicated to both BSE Limited and National Stock Exchange of India Limited as per regulatory requirements under SEBI LODR Regulations.

Professional Background and Experience

Mr. Samsheer Kumar Deo brings substantial industry experience to his new role at Alkem Laboratories. His professional credentials include:

• Experience: Over 29 years of experience in sales functions
• Educational Background: Bachelor of Science (B.Sc.) degree from Bhagalpur University, completed in 1992
• Key Strength: Instrumental in strengthening performance by handling sales function

Regulatory Compliance

The appointment disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under Schedule III, Part A of the SEBI LODR Regulations and SEBI Master Circular bearing reference number HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.

The disclosure was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, and the information has been made available on the company's official website at www.alkemlabs.com for stakeholder access.

Alkem laboratories has announced the receipt of a Certificate of GMP Compliance from the Malta Medicines Authority for its manufacturing facility located at Daman, India. The pharmaceutical company informed stock exchanges about this regulatory milestone on March 20, 2026, pursuant to Regulation 30 of the SEBI LODR Regulations.

Certificate Details and Validity

The Certificate of GMP Compliance has been issued by the Malta Medicines Authority with respect to the company's Daman manufacturing facility. The certification carries significant operational value as it validates the facility's adherence to European Union Good Manufacturing Practice standards and is valid for 3 years starting December 9, 2025.

Regulatory Timeline

The certification follows a structured regulatory process that began with the GMP inspection conducted on December 9, 2025. Alkem Laboratories had previously informed the exchanges about the Malta Medicines Authority's inspection at its Daman facility through an intimation dated December 10, 2025. The successful completion of this inspection has now resulted in the formal certification.

Compliance and Disclosure

The company has fulfilled its disclosure obligations under the SEBI LODR Regulations by informing both BSE Limited and National Stock Exchange of India Limited about this development. As per regulatory requirements, a copy of this disclosure will be made available on the company's website in accordance with Regulation 30(8) of the SEBI LODR Regulations.

The announcement was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, ensuring proper corporate governance protocols were followed in the disclosure process.